pretranspl
screen
potenti
organ
donor
recipi
essenti
success
solid
organ
transplant
goal
pretranspl
infecti
diseas
screen
identifi
condit
may
disqualifi
either
donor
recipi
identifi
treat
activ
infect
pretranspl
recogn
possibl
defin
risk
infect
develop
strategi
prevent
mitig
posttranspl
infect
implement
prevent
measur
includ
immun
gener
agreement
major
infect
routin
screen
perform
center
vari
extent
infecti
diseas
investig
action
taken
result
potenti
recipi
evalu
infect
risk
obtain
thorough
medic
histori
includ
detail
prior
infect
place
travel
resid
exposur
anim
environment
pathogen
potenti
recipi
undergo
screen
presenc
infect
hiv
hepat
c
hcv
cytomegaloviru
cmv
detail
histori
focu
addit
test
necessari
mitig
prevent
reactiv
latent
infect
posttranspl
pretranspl
recipi
screen
also
help
determin
immun
ill
may
help
alloc
infect
donor
organ
recipi
known
immun
certain
pathogen
pretranspl
period
ideal
time
detail
counsel
recipi
hisher
famili
safe
food
handl
risk
infect
associ
pet
travel
hobbi
garden
woodwork
infect
prevent
approach
includ
hand
hygien
prophylact
antimicrobi
postexposur
prophylaxi
updat
immun
address
well
varieti
pathogen
may
transmit
transplant
tabl
previou
guidelin
pretranspl
screen
develop
number
nation
intern
multidisciplinari
transplant
group
center
diseas
control
prevent
cdc
publish
guidelin
prevent
hiv
transmiss
transplant
process
revis
order
address
updat
knowledg
transmiss
hiv
bloodborn
pathogen
addit
work
ad
hoc
unit
network
organ
sharingorgan
procur
transplant
network
unosoptn
diseas
transmiss
advisori
committe
dtac
help
defin
risk
infect
diseas
transmiss
organ
donat
unit
state
shape
discuss
screen
prevent
measur
convent
screen
strategi
effect
case
guarante
infect
number
incid
infect
report
recent
year
includ
rabi
lymphocyt
choriomening
viru
west
nile
viru
hiv
hcv
renew
discuss
process
organ
donor
screen
addit
dtac
transplant
public
health
commun
initi
help
guid
practic
hope
develop
robust
sentinel
network
detect
respond
donor
transmiss
event
time
manner
guidelin
summar
current
opinion
screen
bacteri
mycobacteri
fungal
parasit
viral
infect
donor
recipi
tabl
detail
discuss
infect
includ
posttranspl
monitor
prophylaxi
treatment
found
section
guidelin
due
lack
expans
avail
organ
pool
despit
steadi
increas
need
organ
replac
diseas
becom
necessari
consid
margin
donor
includ
activ
infect
time
donat
higher
risk
serolog
profil
social
histori
indic
potenti
exposur
bloodborn
pathogen
hiv
hcv
natur
histori
treatment
option
donor
infect
urgenc
transplant
vital
organ
recipi
likelihood
lack
thereof
anoth
organ
offer
patient
transplant
wait
list
must
weigh
determin
accept
potenti
infect
donor
differ
screen
live
donor
deceas
donor
larg
base
differ
time
constraint
evalu
must
take
place
live
donor
often
possibl
treat
activ
infect
delay
transplant
infect
resolv
signific
delay
donor
evalu
transplant
interim
evalu
may
indic
rule
recent
acquir
infect
clinic
reassess
prospect
live
donor
indic
clinic
sign
symptom
possibl
infect
occur
particularli
unexplain
febril
ill
time
initi
screen
plan
date
transplant
cdc
recommend
live
donor
rescreen
hiv
serolog
hiv
nucleic
acid
amplif
test
nat
prior
organ
donat
look
evid
recent
acquir
infect
similarli
consider
given
repeat
serolog
hbv
test
hcv
nat
potenti
live
donor
risk
factor
infect
screen
prospect
live
donor
includ
thorough
medic
social
histori
physic
examin
laboratori
studi
includ
serolog
test
tabl
radiograph
workup
indic
donor
histori
procedur
perform
medic
histori
includ
assess
previou
infect
vaccin
travel
occup
exposur
well
presenc
behavior
pose
risk
bloodborn
sexual
pathogen
exposur
eg
drug
use
sexual
practic
incarcer
live
donor
screen
syphili
hiv
hepat
b
c
tuberculosi
via
tuberculin
ppd
skin
test
releas
assay
igra
suspici
donor
histori
addit
test
may
warrant
consult
transplant
infecti
diseas
specialist
may
help
determin
addit
workup
counsel
manag
await
transplant
anoth
live
donor
avail
contrast
time
frame
deceas
donor
evalu
typic
hour
serolog
workup
perform
laboratori
associ
organ
procur
organ
similar
screen
agenc
hereaft
refer
opo
oper
basi
gener
data
need
determin
donor
suitabl
time
constraint
extens
geograph
area
cover
opo
test
often
limit
serolog
method
rapid
routin
avail
sensit
test
may
avail
infect
hiv
hcv
may
difficult
diagnos
earli
stage
develop
specif
antibodi
thu
comprehens
social
medic
histori
donor
requir
identifi
risk
infect
might
detect
serolog
test
furthermor
certain
infect
may
come
light
transplant
perform
result
routin
procur
cultur
blood
urin
sputum
becom
avail
increasingli
opo
util
rapid
molecular
test
particularli
potenti
donor
includ
nat
test
hcv
hbv
hiv
recent
consensu
confer
util
routin
nat
test
howev
inconclus
larg
due
concern
test
feasibl
within
deceas
donor
timefram
area
well
concern
fals
posit
test
result
potenti
donor
identifi
risk
factor
infect
might
result
wastag
viabl
organ
test
certain
pathogen
particular
geograph
signific
trypanosoma
cruzi
chaga
diseas
endem
mycos
west
nile
viru
may
perform
opo
deceas
donor
uncertain
risk
use
inform
consent
recipi
includ
risk
infect
transmiss
goal
evalu
potenti
live
decreas
donor
diagnos
infect
risk
transmiss
recipi
bacteri
infect
respiratori
tract
urinari
tract
organ
transplant
treat
document
resolut
infect
prior
donat
potenti
kidney
donor
urinari
tract
infect
investig
rule
upper
tract
involv
potenti
donor
histori
suspicion
prior
bloodstream
infect
thorough
investig
perform
insur
infect
present
target
organ
syphili
may
latent
asymptomat
donor
requir
therapi
time
permit
syphili
rare
transmit
transplant
contraind
organ
donat
recipi
treat
posttranspl
appropri
cours
penicillin
deceas
donor
may
harbor
known
unsuspect
bacteri
infect
attempt
rule
presenc
activ
infect
includ
obtain
detail
histori
donor
famili
recent
contact
possibl
primari
care
physician
well
complet
review
medic
record
vital
sign
physic
exam
radiograph
studi
avail
microbiolog
studi
blood
cultur
obtain
rule
occult
donor
bacteremia
bacteremia
virul
organ
staphylococcu
aureu
pseudomona
aeruginosa
may
result
earli
posttranspl
sepsi
mycot
aneurysm
format
site
allograft
vascular
anastomos
although
review
bacterem
donor
found
evid
transmiss
recipi
treat
antimicrobi
therapi
mean
day
posttranspl
standard
care
administ
longer
cours
therapi
recipi
eg
week
donor
known
bacterem
virul
organ
gener
reason
treat
recipi
allograft
deceas
donor
nonbacterem
local
infect
involv
transplant
organ
except
mening
occult
bacteremia
frequent
occur
iii
organ
success
transplant
donor
bacteri
mening
due
pathogen
streptococcu
pneumonia
appropri
antimicrobi
therapi
administ
donor
recipi
lung
transplant
deserv
special
attent
donor
bacteri
colon
common
lung
contact
extern
environ
airway
colon
multipl
organ
increas
resist
note
hospit
critic
ill
potenti
organ
donor
donor
bronchoscopi
cultur
perform
time
evalu
andor
procur
allow
administr
antibiot
direct
colon
organ
prevent
invas
infect
recipi
iii
allograft
contamin
may
occur
organ
procur
process
interpret
organ
preserv
solut
cultur
challeng
contamin
occur
howev
infect
transmiss
contamin
solut
appear
uncommon
report
kidney
preserv
fluid
contamin
candida
speci
eight
recipi
demonstr
risk
mycot
aneurysm
ruptur
mitig
appropri
antifung
therapi
donor
determin
activ
bacteri
infect
time
procur
antibiot
administ
recipi
least
day
infect
bacilli
staphylococcu
aureu
candida
speci
shorter
cours
therapi
may
consid
less
virul
organ
iii
mycobacterium
tuberculosi
tb
transmit
transplant
largest
studi
date
recipi
donor
transmiss
account
approxim
report
posttranspl
tb
case
potenti
live
donor
ppd
test
perform
tuberculin
skin
test
endem
area
tb
releas
assay
igra
test
either
test
posit
addit
test
perform
rule
presenc
activ
infect
iii
donor
activ
tuberculosi
exclud
donat
therapi
complet
sign
infect
resolv
posit
ppd
defin
presenc
h
mm
indur
immunosuppress
patient
contact
person
activ
tb
mm
inject
drug
user
employe
resid
hospit
nurs
home
group
set
children
age
mm
other
potenti
donor
evid
latent
tb
infect
ie
posit
ppd
posit
igra
test
chest
radiograph
look
evid
activ
pulmonari
infect
symptom
infect
radiograph
find
suggest
activ
diseas
acid
fast
bacilli
afb
cultur
sputum
andor
appropri
specimen
perform
potenti
kidney
donor
evid
latent
tb
infect
ltbi
could
includ
urin
afb
cultur
abdomin
ct
scan
sign
symptom
activ
diseas
chest
radiograph
normal
sputum
afb
cultur
indic
due
low
yield
manag
prospect
live
donor
ltbi
vari
degre
local
endem
delay
transplant
live
donor
treat
isoniazid
month
rifampin
month
isoniazid
rifapentin
month
appropri
anoth
suitabl
donor
avail
tb
endem
area
mani
donor
ltbi
may
difficult
avoid
use
infect
donor
isoniazid
prophylaxi
recipi
organ
live
donor
ltbi
option
control
studi
need
determin
efficaci
practic
iii
deceas
donor
time
allow
tuberculin
skin
test
igra
logist
practic
case
donor
activ
tuberculosi
clinic
possibl
util
case
potenti
donor
known
recent
ppd
skin
test
convers
suggest
recent
acquisit
infect
potenti
high
organ
burden
transplant
approach
caution
due
risk
dissemin
recipi
donor
histori
untreat
posit
ppd
without
evid
activ
diseas
accept
warrant
consider
treatment
recipi
isoniazid
iii
new
guidelin
prevent
manag
mycobacterium
tuberculosi
organ
transplant
publish
american
journal
transplant
activ
system
fungal
infect
donor
contraind
transplant
endem
mycos
may
difficult
diagnos
infect
may
dormant
transmiss
histoplasmosi
transplant
describ
case
appear
result
reactiv
past
infect
recipi
mani
individu
midwestern
unit
state
calcifi
pulmonari
hilar
splenic
granulomata
radiograph
residua
old
histoplasma
infect
sign
tradit
consid
contraind
donat
iii
transmiss
coccidioidomycosi
lung
transplant
report
southwestern
unit
state
although
reactiv
coccidioidomycosi
previous
infect
recipi
appear
far
common
uniform
recommend
donor
screen
endem
mycos
toxoplasmosi
signific
issu
heart
transplant
recipi
heart
highest
risk
develop
activ
toxoplasmosi
posttranspl
toxoplasmosi
also
rare
transmit
liver
kidney
recipi
donor
seroposit
contraind
heart
donat
allow
appropri
prophylaxi
administ
recipi
routin
prophylaxi
pneumocysti
jiroveci
effect
prevent
toxoplasmosi
may
negat
need
serolog
test
area
low
preval
screen
donor
toxoplasma
routin
perform
noncardiac
donor
part
screen
panel
transplant
center
opo
transmiss
chaga
diseas
trypanosoma
cruzi
transplant
signific
problem
endem
area
mexico
central
south
america
increasingli
report
unit
state
recent
consensu
confer
result
recommend
includ
avoid
transplant
heart
infect
donor
monitor
recipi
pcr
microscopi
buffi
coat
detect
earli
infect
initi
therapi
serolog
statu
donor
recipi
crucial
determin
risk
infect
screen
viral
infect
donor
recipi
discuss
togeth
detail
tabl
caution
use
interpret
antibodi
statu
infant
due
role
matern
antibodi
detail
inform
clinic
present
treatment
infect
found
elsewher
guidelin
cmv
serolog
statu
donor
recipi
import
predictor
posttranspl
infect
cmv
seroneg
recipi
cmv
seroposit
donor
organ
highest
risk
develop
cmv
recurr
cmv
cmv
consequ
donor
recipi
test
cmv
infect
use
commonli
avail
serolog
techniqu
contraind
transplant
statu
indic
intens
monitor
prevent
strategi
posttranspl
donorrecipi
pair
lower
risk
cmv
infect
seroposit
recipi
regardless
donor
statu
risk
cmv
reactiv
usual
receiv
either
prophylaxi
preemptiv
monitor
therapi
mani
differ
protocol
use
full
discuss
cmv
prevent
treatment
found
elsewher
guidelin
primari
ebv
infect
sever
dissemin
posttranspl
set
develop
posttranspl
lymphoprolif
diseas
ptld
fear
complic
highest
ptld
risk
ebv
seroneg
recipi
ebv
seroposit
graft
commonli
occur
pediatr
recipi
risk
ptld
also
increas
seroposit
recipi
especi
influenc
potent
immunosuppress
antithymocyt
globulin
atg
belatacept
awar
pretranspl
serolog
help
target
highest
risk
group
close
monitor
preemptiv
intervent
decreas
immunosuppress
ebv
serolog
perform
donor
recipi
order
defin
risk
posttranspl
lymphoma
british
transplant
societi
british
committe
standard
haematolog
recent
publish
extens
guidelin
pretranspl
screen
diagnosi
ptld
organ
transplant
recipi
herpesvirus
clinic
import
transplant
recipi
includ
herp
simplex
viru
viru
vzv
human
hsv
screen
perform
center
wherea
center
administ
univers
antivir
prophylaxi
least
first
month
posttranspl
primari
varicella
infect
posttranspl
fatal
vzv
screen
recipi
import
vaccin
seroneg
recipi
pretranspl
possibl
iii
recent
awar
possibl
role
cofactor
cmv
effect
fungal
infect
possibl
allograft
dysfunct
led
increas
interest
virus
sinc
almost
adult
seroposit
howev
donor
recipi
screen
virus
gener
recommend
whether
screen
would
help
pediatr
transplant
program
unknown
agent
kaposi
sarcoma
reactiv
transplant
may
transmit
transplant
seropreval
vari
wide
accord
popul
studi
optim
strategi
prevent
reactiv
defin
thu
definit
recommend
pretranspl
screen
made
time
donor
recipi
test
hepat
b
use
standard
serolog
techniqu
complex
issu
surround
hbv
transplant
discuss
detail
hepat
section
guidelin
donor
screen
includ
least
hepat
b
surfac
antigen
hbsag
hbv
core
antibodi
hbcab
perform
separ
igg
igm
use
donor
hbsag
posit
posit
indic
activ
hbv
infect
hbsag
neg
posit
person
may
window
period
donor
gener
util
although
center
use
donor
recipi
evid
immun
hepat
b
posit
hepat
b
surfac
antibodi
hbsab
andor
intens
posttranspl
prophylaxi
monitor
isol
hbsab
posit
usual
indic
prior
vaccin
resolv
infect
gener
consid
risk
hbv
transmiss
complex
question
use
hbsag
neg
posit
donor
donor
may
repres
either
test
isol
hbcab
posit
presenc
chronic
hbv
infect
latter
signific
risk
transmiss
hbv
liver
transplant
recipi
therefor
liver
often
util
past
howev
becom
common
transplant
liver
hbcab
posit
donor
util
intens
posttranspl
prophylaxi
risk
transmiss
extrahepat
recipi
appear
low
occur
risk
decreas
pretranspl
hbv
vaccin
recipi
center
restrict
use
organ
donor
situat
andor
vaccin
recipi
would
util
posttranspl
prophylaxi
hepat
b
immun
globulin
hbig
andor
lamivudin
transplant
nonimmun
recipi
possibl
offer
organ
prudent
vaccin
seroneg
transplant
candid
hbv
vaccin
although
respons
vaccin
patient
organ
diseas
may
suboptim
requir
higher
dose
repeat
inject
attain
immun
iii
donor
level
provid
help
inform
design
prophylact
strategi
even
result
receiv
transplant
addit
inform
prophylact
strategi
may
found
hepat
section
guidelin
see
chapter
recipi
screen
hbv
help
posttranspl
manag
patient
undergo
liver
transplant
liver
diseas
due
hbv
varieti
posttranspl
protocol
prevent
reactiv
hbv
mani
util
hbig
andor
antivir
agent
extrahepat
transplant
hbsag
posit
recipi
controversi
earli
day
kidney
transplant
transplant
perform
result
earli
fulmin
hepat
recipi
chronic
liver
diseas
mani
maintain
asymptomat
statu
mani
year
despit
evid
activ
viral
replic
effect
antivir
therapi
lamivudin
adefovir
tenofovir
avail
appear
theoret
possibl
transplant
recipi
safe
although
antivir
resist
may
becom
issu
iii
hcv
infect
frequent
chronic
donor
recipi
test
presenc
hcv
via
standard
serolog
techniqu
hcv
major
indic
liver
transplant
although
hcv
recurr
common
posttranspl
patient
allograft
surviv
significantli
wors
pretranspl
diagnos
hcv
seroposit
renal
transplant
candid
higher
risk
liver
diseas
sepsi
transplant
hcv
seroneg
counterpart
compar
transplant
altern
risk
outweigh
benefit
case
role
pretranspl
treatment
hcv
viremia
remain
studi
strategi
manag
hcv
recipi
discuss
detail
elsewher
guidelin
see
chapter
util
hepat
c
donor
remain
controversi
due
high
risk
transmiss
hcv
transplant
organ
posit
donor
hcv
nat
indic
activ
viral
replic
associ
higher
risk
transmiss
result
test
may
avail
prior
transplant
deceas
donor
risk
transmiss
nat
neg
hcv
antibodi
posit
donor
yet
fulli
defin
recent
transmiss
event
proven
hcv
transmit
multipl
organ
tissu
transplant
recipi
seroneg
donor
time
infect
antibodi
product
vari
individu
although
viral
rna
present
much
earlier
antibodi
acut
infect
rapid
molecular
test
develop
hope
clarifi
risk
deceas
donor
prior
decis
accept
organ
whenev
hcv
seroposit
donor
util
stringent
inform
consent
advis
donor
util
transplant
due
known
risk
transmiss
recipi
unit
state
use
hiv
seroposit
donor
illeg
serolog
requir
potenti
donor
recipi
rare
unit
state
screen
serolog
frequent
fals
posit
specif
test
viru
perform
donor
recipi
western
africa
endem
western
blot
test
obtain
confirm
posit
screen
test
either
potenti
live
donor
risk
factor
hiv
exposur
neg
hiv
serolog
nat
test
obtain
test
becom
posit
prior
develop
posit
antibodi
test
due
efficaci
highli
activ
antiretrovir
therapi
haart
hiv
infect
recipi
longer
contraind
solid
organ
transplant
multipl
studi
worldwid
includ
multicent
prospect
trial
unit
state
evalu
transplant
stabl
patient
graft
patient
surviv
data
compar
infect
patient
undergo
transplant
meticul
clinic
care
care
attent
pharmacokinet
set
signific
drug
interact
immunosuppress
agent
haart
paramount
success
higher
expect
acut
reject
rate
note
kidney
transplant
recipi
hiv
infect
remain
well
control
patient
graft
surviv
compar
popul
complex
issu
involv
transplant
popul
fulli
discuss
hiv
section
guidelin
see
chapter
endem
certain
part
world
includ
caribbean
japan
part
africa
often
asymptomat
howev
infect
progress
year
even
decad
associ
myelopathytrop
spastic
paraparesi
hamtsp
adult
cell
leukemialymphoma
atl
progress
occur
seroposit
individu
endem
region
respect
viru
like
widespread
geograph
serolog
difficult
distinguish
although
associ
diseas
process
less
certain
screen
deceas
donor
recipi
standard
us
practic
unosoptn
discontinu
requir
perform
prospect
deceas
donor
screen
larg
result
lack
serolog
test
distinguish
despit
low
preval
unit
state
case
infect
occur
signific
neurolog
malign
complic
graft
patient
surviv
recipi
seroposit
donor
organ
note
similar
recipi
seroneg
organ
western
blot
test
nat
may
use
distinguish
may
prevent
unnecessari
wastag
organ
donor
fals
posit
test
result
infect
neither
preclud
donat
howev
report
spain
transmiss
rapid
develop
myelopathi
recipi
suggest
caution
exercis
use
infect
donor
endem
area
recipi
often
test
antibodi
although
littl
known
cours
infect
follow
solid
organ
transplant
case
reactiv
observ
seri
japanes
seroposit
recipi
undergo
renal
transplant
arenaviru
report
sever
cluster
transmiss
multipl
organ
recipi
one
fatal
infect
one
cluster
outbreak
origin
new
pet
hamster
donor
home
date
despit
sever
similar
outbreak
effect
screen
test
rule
infect
lcmv
potenti
organ
donor
develop
cdc
issu
guidelin
minim
risk
lcmv
relat
pet
rodent
transplant
center
consid
possibl
lcmv
infect
donor
asept
mening
well
seemingli
asymptomat
donor
contact
wild
pet
rodent
rabi
anoth
potenti
fatal
infect
outbreak
recipi
transplant
donor
die
subarachnoid
hemorrhag
develop
rapidli
progress
enceph
succumb
infect
retrospect
donor
determin
recent
bat
bite
seroposit
rabi
viru
unit
state
rabi
transmit
commonli
bite
scratch
saliva
exposur
bat
raccoon
skunk
fox
rabi
lcmv
case
rais
question
whether
donor
evalu
includ
inform
exposur
anim
bite
environment
exposur
supplement
alreadi
detail
inform
obtain
highli
fatal
natur
rabi
infect
clinician
encourag
avoid
donor
even
small
possibl
rabi
present
new
respiratori
pathogen
report
caus
sever
diseas
rapid
intern
spread
sar
sever
acut
respiratori
syndrom
found
due
previous
undescrib
coronaviru
nosocomi
household
transmiss
least
affect
patient
requir
mechan
ventil
least
one
transplant
recipi
die
sar
transmiss
transplant
theoret
possibl
extent
risk
unknown
current
principl
donor
recipi
select
would
like
exclud
patient
recent
acut
ill
meet
sar
criteria
howev
consequ
remot
histori
sar
subclin
infect
unknown
screen
tool
potenti
adult
pediatr
donor
propos
expert
toronto
one
major
center
outbreak
took
account
risk
sar
transmiss
donor
hospit
well
donor
symptom
travel
contact
histori
anoth
sar
similarli
transmit
emerg
viru
outbreak
occur
algorithm
would
use
novel
influenza
viru
caus
worldwid
pandem
infect
common
younger
patient
sever
diseas
secondari
bacteri
infect
pregnant
women
underli
chronic
lung
diseas
mani
requir
intens
care
support
impact
pediatr
transplant
consider
prolong
hospit
secondari
infect
yet
report
death
receiv
earli
antivir
therapi
guidelin
pretranspl
screen
potenti
donor
recipi
publish
recommend
screen
donor
symptom
consist
influenza
infect
routin
screen
recommend
due
concern
possibl
donor
transmiss
recommend
donor
receiv
adequ
antivir
therapi
consid
safe
nonlung
small
bowel
donat
empir
treatment
recipi
organ
infect
donor
incomplet
treatment
recommend
pandem
emphas
need
transplant
center
vigil
vaccin
recipi
staff
alert
local
outbreak
diseas
possibl
transmiss
transplant
new
emerg
potenti
communic
agent
may
aris
may
affect
donor
accept
recipi
activ
transplant
list
advis
avoid
transplant
involv
individu
potenti
communic
infect
inadequ
inform
exist
provid
appropri
recommend
regard
precautionari
measur
ancillari
screen
test
emerg
pathogen
sensit
test
known
pathogen
may
propos
guidelin
committe
futur
group
consid
feasibl
test
within
limit
deceas
donor
timefram
well
risk
test
result
could
lead
wastag
otherwis
organ
transplant
recipi
risk
infect
relat
complic
end
organ
failur
patient
await
kidney
transplant
may
infect
hemodialysi
periton
dialysi
access
site
cathet
complic
andor
urinari
infect
candid
await
liver
transplant
risk
aspir
pneumonia
spontan
bacteri
periton
urinari
tract
infect
infect
associ
intraven
cathet
pancrea
transplant
candid
develop
diabet
foot
infect
associ
osteomyel
await
heart
transplant
may
infect
relat
either
indwel
intraven
cathet
ventricular
assist
devic
vad
util
bridg
transplant
addit
heart
candid
also
risk
pneumonia
set
congest
heart
failur
debilit
vad
ventricular
infect
contraind
transplant
complet
remov
vad
time
transplant
combin
appropri
posttranspl
antibiot
therapi
often
cur
screen
lung
transplant
recipi
includ
assess
colon
airway
flora
care
review
previou
pulmonari
infect
cystic
fibrosi
patient
may
colon
strain
pseudomona
andor
burkholderia
cepacia
well
organ
staphylococcu
aureu
alcaligen
klebsiella
acinetobact
stenotrophomona
aspergillu
scedosporium
knowledg
pretranspl
colon
flora
assist
develop
individu
prophylact
antimicrobi
regimen
controversi
whether
patient
colon
burkholderia
exclud
receiv
lung
transplant
molecular
type
burkholderia
isol
may
use
defin
risk
genomovar
iii
b
cenocepacia
associ
highest
risk
poor
outcom
transplant
patient
ppd
tuberculin
skin
test
perform
prior
transplant
posit
skin
test
histori
activ
tuberculosi
undergo
addit
screen
rule
activ
diseas
releas
assay
igra
may
particularli
use
assess
patient
receiv
bacillu
bcg
vaccin
igra
assay
potenti
distinguish
ppd
posit
relat
bcg
relat
latent
tb
infect
age
patient
ltbi
given
prophylaxi
prevent
reactiv
diseas
set
immunosuppress
detail
treatment
ltbi
found
tuberculosi
section
guidelin
chapter
transplant
candid
clinic
histori
radiograph
andor
cultur
suggest
infect
tb
nontubercul
mycobacteria
thorough
evalu
activ
diseas
perform
may
includ
ct
scan
bronchoscopi
test
deem
clinic
necessari
mycobacteri
infect
optim
treat
document
microbiolog
radiograph
resolut
transplant
consid
pretranspl
colon
fungi
aspergillu
common
lung
transplant
recipi
particularli
cystic
fibrosi
patient
colon
prompt
rigor
evalu
exclud
activ
infect
although
posttranspl
aspergillosi
fear
complic
transplant
clinician
gener
reli
posttranspl
preemptiv
prophylact
strategi
rather
pretranspl
antifung
therapi
colon
patient
pretranspl
candid
invas
fungal
infect
rather
colon
treat
least
radiograph
clinic
microbiolog
resolut
order
minim
risk
infect
posttranspl
iii
addit
inform
diagnosi
prevent
treatment
infect
aspergillu
found
part
guidelin
pretranspl
screen
endem
mycos
use
area
endem
coccidioidomycosi
pretranspl
histori
activ
diseas
andor
seroposit
may
prompt
lifelong
azol
prophylaxi
pretranspl
screen
histoplasmosi
limit
valu
sinc
latent
histoplasmosi
may
present
neg
serolog
iii
instead
heighten
awar
possibl
histoplasmosi
import
investig
posttranspl
febril
ill
patient
endem
area
patient
prolong
travel
histori
endem
area
strongyloidiasi
includ
tropic
countri
part
southeastern
unit
state
risk
develop
dissemin
strongyloidiasi
transplant
screen
serolog
strongyloid
much
sensit
stool
exam
recommend
epidemiolog
risk
iii
seroposit
patient
short
cours
ivermectin
thiabendazol
indic
pretranspl
although
random
data
avail
discuss
toxoplasma
serolog
perform
heart
transplant
candid
seroneg
heart
recipi
seroposit
donor
receiv
prophylaxi
chaga
diseas
parasit
infect
fulli
discuss
elsewher
guidelin
see
chapter
activ
primari
infect
virus
cmv
ebv
hbv
time
transplant
uncommon
nonetheless
activ
viral
infect
detect
potenti
recipi
transplant
like
delay
infect
resolv
order
allow
develop
natur
immun
prior
transplant
immunosuppress
iii
recommend
also
extend
candid
present
transplant
clinic
symptom
suggest
acut
viral
infect
chanc
exposur
hiv
pretranspl
potenti
recipi
hiv
nat
hiv
antibodi
test
perform
iii
viral
screen
donor
recipi
discuss
detail
pretranspl
evalu
present
import
opportun
updat
potenti
recipi
immun
sinc
vaccin
effect
administ
prior
onset
transplant
immunosuppress
detail
immun
recommend
summar
anoth
section
guidelin
see
chapter
potenti
recipi
screen
infect
vaccin
possibl
prior
transplant
candid
ideal
immun
varicella
prior
transplant
howev
transplant
expect
immin
may
best
withhold
vaccin
live
attenu
vaccin
iii
zoster
vaccin
also
live
vaccin
current
licens
older
adult
immunocompromis
data
await
regard
whether
pretranspl
zoster
vaccin
prevent
posttranspl
zoster
reactiv
present
time
would
appear
reason
administ
zoster
vaccin
transplant
candid
meet
current
criteria
vaccin
transplant
expect
within
week
hepat
b
vaccin
seri
ideal
administ
pretranspl
seroneg
individu
especi
potenti
donor
may
found
hbsag
neg
hbcab
posit
dialysi
patient
formul
given
patient
advanc
liver
diseas
particularli
high
risk
fulmin
hepat
receiv
hepat
vaccin
vaccin
like
effect
administ
earli
liver
diseas
combin
hepat
b
vaccin
immunogen
data
await
transplant
candid
recipi
mmr
vaccin
contain
live
viru
patient
born
presum
natur
immun
patient
born
receiv
second
dose
mmr
vaccin
receiv
second
dose
given
rather
posttranspl
iii
pneumococc
vaccin
also
administ
transplant
candid
age
receiv
within
past
year
iii
tdap
pertussi
vaccin
administ
potenti
adult
recipi
toxoid
td
booster
within
year
consid
potenti
recipi
light
increas
pertussi
case
recent
year
iii
prevent
strategi
infect
confin
medic
vaccin
extens
educ
transplant
recipi
famili
import
prevent
tool
pretranspl
class
print
materi
help
includ
inform
handwashinghand
hygien
environment
exposur
activ
avoid
food
safeti
handl
foodborn
pathogen
pet
travel
also
help
patient
gener
idea
infect
transplant
patient
suscept
prevent
strategi
use
particular
center
fundament
patient
know
expect
go
wrong
expect
pretranspl
screen
potenti
organ
donor
recipi
afford
opportun
assess
feasibl
safeti
transplant
determin
prophylaxi
prevent
strategi
util
posttranspl
detect
fulli
treat
activ
infect
potenti
recipi
prior
transplant
updat
vaccin
statu
potenti
recipi
suffici
educ
patient
famili
prevent
measur
futur
advanc
incorpor
increas
use
rapid
molecular
diagnost
test
possibl
ancillari
test
emerg
pathogen
clinic
practic
author
manuscript
conflict
interest
disclos
describ
american
journal
transplant
